



21 June 2016

ASX ANNOUNCEMENT

Vive La France: Regulatory Approval Received

Medical Developments International Limited (ASX: MVP) is delighted to announce it has received Marketing Authorisation for Pentrox in France for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

MVP CEO, Mr John Sharman, said: "This is an exciting achievement for MVP. With French approval we can begin to sell product in France and Belgium. Preparations for the launch of Pentrox in France and Belgium are well advanced."

Mr Sharman said: "The approval in France is another step towards selling Pentrox into key global markets around the world. The approval triggers another milestone payment of \$USD 3.0 million from Mundipharma, our partner in Europe."

Kate Hurtig, Head of Pain at Mundipharma International added: "Mundipharma has a proud heritage in pain management and is committed to advancing important new therapeutics in this space. We are excited about the opportunity to begin to sell Pentrox in Europe and the prospect for growth which that brings."

The Chairman of MVP, David Williams, said: "French approval is a red-letter day for MVP, not because we can now sell in France, but because it also signals the start of our quest for the approval in 28 other countries in the EU that we will seek as part of the Decentralised Approval process".

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 3 9547 1888



About Pentrox

Penthrox is a fast onset, non-opioid analgesic which is indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5 million units sold. Mundipharma International has exclusive product rights in 39 European markets (including France, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom).

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Mundipharma

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.